miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 16, 2025

Stock market today: Dow, S&P 500 slip as unemployment rate rises, Tesla marches toward record

View original at finance.yahoo.com
Stock market today: Dow, S&P 500 slip as unemployment rate rises, Tesla marches toward record US stocks diverged on Tuesday after investors saw a mixed picture from updates on the labor market…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Oil prices could drop into $40s or $30s per barrel if OPEC+ doesn't cut and other producers don't slow down

    80% confidence
  • Need to be careful in assessing household survey data and look at it with a skeptical eye

    80% confidence
  • Secured a deal for US security guarantees in bid to end the war

    80% confidence
  • Bitcoin trading in choppy range with continued lack of interest and low volumes across crypto markets

    80% confidence
  • The Amazon partnership renewal was largely in line with the current program

    80% confidence
  • Pretty big margin of error in November jobs report data, likely to see revisions in January

    80% confidence
  • Brent oil prices will slip into $50s per barrel in 2026, possibly into $40s or $30s

    80% confidence
  • Difficult to see a re-rating catalyst for Pfizer as company works through multi-year loss of exclusivity period

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stock market today: Dow, S&P 500 slip as unemployment rate rises, Tesla marches toward record — Source | Via News | es.VIA.NEWS